给药时间对瑞舒伐他汀与依折麦布联合治疗高胆固醇血症疗效的影响(RosEze):随机对照试验研究方案
RosEze 是一项随机、开放标签、单中心、交叉研究,计划纳入 200 例经他汀治疗至少 6 周仍控制不佳的高胆固醇血症患者,比较晨间(8:00)与晚间(8:00)服用瑞舒伐他汀联合依折麦布对 LDL-C 等指标的影响,主要结局为治疗 6 周和 12 周时 LDL-C 的变化。
要点
- 研究比较瑞舒伐他汀联合依折麦布晨间(8:00)与晚间(8:00)给药对 LDL-C 的影响。
- 计划纳入 200 例经他汀治疗至少 6 周仍未达标的高胆固醇血症患者。
- 主要结局为治疗 6 周和 12 周时 LDL-C 变化,取决于每日给药时间。
核心结论
- RosEze 试验旨在验证晨间与晚间服用瑞舒伐他汀联合依折麦布在降低胆固醇浓度方面是否存在显著疗效差异。
研究设计与样本
- 随机、开放标签、单中心、交叉研究,计划纳入 200 例经他汀治疗至少 6 周仍控制不佳的高胆固醇血症患者。
- 入组后随机分为两组:第一组先晨间(8:00)服药 6 周,再晚间服药 6 周;第二组先晚间(8:00)服药 6 周,再晨间服药 6 周。
- 所有患者免费获得研究药物以减少不依从。
主要发现
- 主要结局为治疗 6 周和 12 周时 LDL-C 的变化,取决于每日给药时间。
- 次要终点包括治疗 6 周和 12 周时总胆固醇、HDL 胆固醇、甘油三酯、载脂蛋白 ApoB 和 Apo AI、非 HDL 胆固醇、小而密(sd)-LDL 胆固醇、脂蛋白(a)、葡萄糖、糖化血红蛋白、高敏 C 反应蛋白、天冬氨酸氨基转移酶、丙氨酸氨基转移酶、γ-谷氨酰转移酶和肌酸激酶的变化。
- 次要终点还包括基线和治疗 6 周、12 周时用稳态和时间分辨荧光光谱评估血浆荧光。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypercholesterolemia is one of the main risk factors for cardiovascular disease. The first line treatment for hypercholesterolemia is statin therapy. When the expected low-density lipoprotein cholesterol (LDL-C) concentration is not achieved, the pharmacotherapy may be extended by combining the statin with the cholesterol absorption inhibitor ezetimibe. METHODS/DESIGN: The study is designed as a randomized, open-label, single-center, crossover study evaluating the effectiveness of combined therapy with rosuvastatin and ezetimibe for hypercholesterolemia. The study is planned to include 200 patients with hypercholesterolemia ineffectively treated with statins for at least 6 weeks. After enrollment participants are randomized into one of two arms receiving rosuvastatin and ezetimibe. In the first arm the study drug is administered in the morning (8:00 am) for 6 weeks and then in the evening for the next 6 weeks; in the second arm the study drug is administered at first in the evening (8:00 pm) for the first 6 weeks and then in the morning for the following 6 weeks. In order to minimize non-adherence to the treatment, all patients will receive the study drug free of charge. The primary outcome of the study is change in LDL-C at 6 and 12 weeks of the treatment, depending on the time of day of study drug administration. The secondary endpoints include change in total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins ApoB and Apo AI, non-HDL cholesterol, small, dense (sd)-LDL cholesterol, lipoprotein(a), glucose, glycated hemoglobin, high-sensitivity C-reactive protein, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, and creatine kinase at 6 and 12 weeks of the study drug treatment, as well as assessment of plasma fluorescence using stationary and time-resolved fluorescence spectroscopy at baseline and at 6 and 12 weeks of the therapy. DISCUSSION: The RosEze trial is expected to demonstrate whether there is a significant difference in the effectiveness of the lipid-lowering therapy in reducing the concentration of cholesterol when the medications are taken in the morning compared with the evening time of day. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02772640 . Registered on 28 March 2016.
引用
- Obońska K, Kasprzak M, Sikora J, et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28697767. doi:10.1186/s13063-017-2047-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。